Oct 30th Day 2

09:04

Controlling Infectious Diseases

09:04

Evaluating RSV vaccine candidates: What is missing?

09:04

Formulation and Analytical Approaches

09:04

Promising Immunotherapy Approaches

09:04

Targeted Vaccine Developments

09:04

Veterinary Vaccine Technologies

Veterinary
10:20

Ensuring compliance of veterinary vaccines

10:35

Morning Networking Break

Influenza & Respiratory
11:35

Human challenge models for RSV; benefits and limitations

Immuno-oncology
11:35

Insight on future combination strategies

- Are we effectively incorporating profiling techniques into R&D to better understand the underlying cellular mechanisms and “build” better combinations?
12:34

Manufacturing Platforms & Practices

13:04

Profiling & Response

Immuno-oncology
13:05

Biomarker strategies for patient selection

- Rationale for creating a reference standard for biomarker assays- Clinical implementation of biomarker assays - How do we get these assays up and running in clinical practice?

Serafino Pantano, Director, Biomarker And Diagnostics Leader, MSD
13:35

Networking Lunch & Poster Session

15:04

Vector-borne and parasitic diseases

Emerging Diseases
15:05

Norovirus vaccines in development

Sean Tucker, Chief Scientific Officer And Vice President Research, Vaxart
15:34

Global Health Manufacture

16:05

Afternoon Networking Break

16:34

Big Data & Cancer Immunotherapy

17:04

Managing Bacterial Diseases

Bioprocess & Manufacture
17:05

Delivery platforms catered for the developing countries

18:15

Chair closing remarks of day two followed by Drinks Reception host by Neomed Labs

last published: 18/Oct/19 14:55 GMT